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INTRODUCTION
Injecting drug use (IDU) represents the most common risk factor for HCV infection throughout the industrialized world. [1] However, a substantial proportion of persons who test HCV antibody-positive report no risk factors for acquiring infection. In the United States, 30% of persons with acute HCV during 1991-1995 denied a specific exposure associated with becoming infected during the six months preceding illness onset, although over half of these reported a history of drug use. [2] In England and Wales, 71% (35598/49819) of confirmed HCV infections during 1992-2004 lacked risk factor information. [3] Sentinel surveillance of acute HCV infection in the United States indicates sexual risk behaviour as a probable route of infection in a significant minority of cases [4, 5] . Either the potential risk factors for HCV acquisition were not carefully elicited in these studies, or there was a significant undefined source of viral transmission. A study in the United States showed that the route of HCV acquisition could be delineated in 88% of HCV chronically infected patients using a systematic interview approach; in nearly all cases, the initially unreported risk factor for HCV transmission was a remote history of injecting drug use. [6] Deriving an estimate of the percentage of HCV-diagnosed persons with IDU risk from the observed data can be problematic (i.e., subject to bias) if there is a large amount of missing risk information, which is the case for the national HCV diagnosis database held by Health Protection Scotland (HPS), a population-wide record of all individuals testing HCV antibodypositive since testing commenced in 1991. As at the end of 2009, 35% of records lacked data on risk factor(s), and of those with risk information, current/former IDU was specified for 89%. [7] An unknown percentage of persons with missing risk data will have acquired their infection through IDU.
In the current study, we combined data on injecting drug use history available from four other data sources -HIV testing, hospital discharges, deaths, treatment for drugs misuse -with that on the HCV diagnoses database, using record-linkage methods to identify individuals observed across sources. The total number of HCV-diagnosed persons with IDU risk was then estimated using capture-recapture statistical methods, [8] originally developed for counting animal populations. Thus, the purpose of our study was to estimate of the proportion of HCV antibody-positive and diagnosed persons who were likely to have acquired their infection through injecting drug use, which will provide public health policy-makers with a more accurate demographic picture of Scotland's HCV-infected population, and will consequently inform on resource allocation for prevention, treatment and care.
METHODS
The IDU status of HCV-diagnosed persons was sourced from five databases (i.e. HCV diagnoses, HIV tests, treatment for drug misuse, hospital discharges, and deaths databases).
Data on opiate use rather than injecting drug use per se was available from the latter two databases, and served as a proxy indicator for IDU. The second data source used was the national HIV test database, also held by HPS. It records all HIV tests conducted within Scotland, excluding routine screening (e.g., antenatal, renal, travel/insurance), and persons under 15 years of age. Data is provided by all NHS laboratories in Scotland that perform HIV testing. Individual records on this database contain the following non-named information: sex, date of birth, surname and forename initials, health board of residence (HB; NHS Scotland administrative area) and a hospital/clinic number generated from GUM clinic/hospital referrals only, as well as data concerning risk activities. HIV Test records were mapped to distinct individuals using a deterministic approach (i.e., the procedure required a complete match on either the set of identifiers sex, date of birth, and initials, or the set of sex, date of birth, and hospital/clinic number). The HIV Test database contained records for 523251 HIV tests conducted between 1 January 1988 and 31 December 2009 (including the testing of some stored sera back to 1980). Internal linkage resulted in records for 412994 distinct HIVtested individuals. Linkage between the HCV Diagnosis and HIV Test databases was also performed in-house at HPS using deterministic methods (i.e., a complete match was required on the identifier set (i) sex, date of birth, and initials; or, if initials were missing, the set (ii) sex, date of birth, and hospital/clinic number).
The Scottish Morbidity Records (SMR01) is an episode-based patient record of all acute inpatient and day case hospital discharges from non-obstetric, non-psychiatric specialities.
Information Services Division (ISD) routinely combines SMR01 data with death registrations held by the General Register Office for Scotland to form a linked dataset; the identifiers sex, date of birth, initials, and surname Soundex were available. We treated this linked dataset (of hospital and death records) as a single data source for the capture-recapture analysis. Linkage of records between the HCV Diagnosis database and the hospitalisation/deaths dataset was carried out by ISD using probabilistic record-linkage techniques, [9] which allow for matches using incomplete identifiers. All hospital and death records (for the period 1 January 1981 to 31
December 2009) that had linked to HCV diagnosed persons were provided for analysis.
The final data source used was the Scottish Drug Misuse Database (SDMD), also held by ISD.
The SDMD is a record of current/former drug users in contact with drug treatment and support services, including general practitioners, hospitals, specialist drug clinics, and non-statutory agencies. These agencies report information on new contacts (defined as first presentation or repeat presentation if it has been at least six months since last attendance) to the SDMD. The IDU risk for an individual on the SDMD was defined according to self-report: if at any attendance at drug services the client reported having either 'injected in the previous month' or 'injected in past/not previous month', he/she was classified as having IDU risk.
Statistical methods
Log-linear modelling [8] was used to analyse the overlap in the number of HCV-diagnosed persons with IDU risk among the four data-sources (HCV diagnosis, HIV test, hospital/death and SDMD) and estimate the total population size (i.e., the number of HCV diagnosed IDUs including those who are unknown). Backwards stepwise regression was used to find a model which adequately described the data with the least number of parameters; 2-way and 3-way interaction terms were removed from the model specification if the Akaike Information Criterion (AIC) difference was <2 compared with the model including the interaction term.
Confidence intervals were determined using the profile likelihood. Model fitting was done using the Rcapture package [10] for R statistical software. [11] Stratified log-linear analyses were conducted according to four covariates: sex, birth cohort (<1960, 1960-1969, 1970-1979, 1980+) 
RESULTS

Study population
Among all HCV-diagnosed persons, 58% (14836/25521) reported IDU risk at the time of their HCV diagnosis, 7.3% (1862/25521) reported a non-IDU risk (e.g. blood factor/transfusion) and for 35% the risk factor(s) for acquiring infection were unknown. Among those with a reported risk(s) on the HCV Diagnosis database, 89% (14836/16698) were current/former IDUs. The majority of HCV-diagnosed persons were male (68%), and were born during the 1960s and 1970s (70%) ( Table 1) .
IDU risk from other data sources
Of the 25521 HCV-diagnosed persons, 38%, 49% and 30% were identified as having an IDU risk on the HIV test, SDMD and hospital/deaths databases, respectively (Table 1) . Among HCVdiagnosed persons who had reported a non-IDU risk at the time of HCV diagnosis, 11% (200/1862), 16% (294/1862) and 9% (171/1862) were identified as having IDU risk on the HIV test, SDMD and hospitalisation/deaths databases, respectively. The distribution of covariates across data sources varied somewhat for birth cohort (Table 1) . Twenty per cent of all HCVdiagnosed persons were born prior to the 1960s, compared to only 6% of those identified with IDU risk on the SDMD, and 10% of those with IDU risk on either the HCV Diagnosis or hospitalisation/deaths data sources. Across data sources, the proportion of individuals with an IDU risk residing in Greater Glasgow & Clyde health board was relatively constant, at 40% to 46%, as was the proportion of males, at 69% to 74%.
Of the 25521 HCV-diagnosed persons, 18782 (74%) had IDU risk recorded on at least one of the four data-sources (i.e. on either the HCV diagnosis, HIV test, SDMD or hospital/deaths databases). Overall sensitivity of the HCV Diagnosis database for recording IDU risk (with respect to the 'gold standard' of IDU status determined from any of the four linked datasources) was 79.0%, which varied according to covariate level (Table 1) .
Log-linear modelling
The log-linear model fitting procedure retained all 2-way and 3-way interaction terms, and predicted a further 2484 IDUs not identified from the four data sources (Table 2) Table 2 ).
Stratified log-linear models fitted to the data according to sex, birth cohort, period of HCV diagnosis, and HB group indicated substantial variation in estimated IDU prevalence (Table 3) .
Prevalence was lowest for the oldest cohort (born before 1960, 49.4%) and highest for individuals born 1970-79 (93.4%). Estimated prevalence was also highest for males (84.6%) and for persons diagnosed with HCV during 1995-1999 (91.5%).
DISCUSSION
This application in Scotland is the first to demonstrate the use of log-linear modelling, based on capture-recapture data from four linked sources, to estimate the proportion of IDUs among HCV diagnosed persons. The estimated prevalence of current/former IDU was 83% in Scotland's HCV-diagnosed population, substantially higher than the 58% who had reported IDU as risk activity. This estimated prevalence was somewhat lower than an estimate of IDU prevalence derived from the 65% of the study population with reported risk factor(s) (89%). However, if individuals diagnosed with HCV in the three most recent years of the study period are excluded (to allow more opportunity for 'capture' by the other data sources), the prevalence was estimated at 85%. The latter figure is closely comparable to the value (87%) obtained from laboratory surveillance in England & Wales in 1992-2004. [3] Stratified analyses indicated that estimated IDU prevalence was lowest (67%) among individuals diagnosed with HCV before 1995; this is consistent with an over-representative contribution to the early growth of the database from persons with blood clotting disorders. IDU prevalence was highest among those born in the 1960s and 1970s, reflecting the age-groups in Scotland in which problem drug use is the most prevalent, [12] and in which risky injecting practices are frequent. [13] Estimated IDU prevalence was also higher for male, compared with female, HCV diagnosed persons (86% and 78%, respectively), which may be due to male sex being an independent risk factor for acquiring HCV infection among IDUs, leading to more male than female HCV-infected IDUs appearing on the HCV Diagnosis database.
The estimated sensitivity of the risk information field in the HCV Diagnosis database also varied according to birth cohort, and period of diagnosis, with the lowest accuracy observed for the youngest cohort (74%) and most recent HCV diagnosis period (69%); the latter finding is consistent with there sometimes being a short lag in the collection and recording of risk activity data on the HCV Diagnosis database..
The only other study we are aware of in which the number of HCV-infected IDUs was estimated using capture-recapture methods was conducted in Porto Alegre, Brazil. [14] In this study, the total number of IDUs attending syringe-exchange programmes was estimated based on two interviewed samples approximately one month apart, and then overall HCV seroprevalence in this population (53%) was assumed for the estimated total IDUs (168/317). However, the proportion of IDU risk among HCV-diagnosed persons was not estimated in the study.
Although the application of capture-recapture and log-linear modelling methods to epidemiological questions has certain strengths, it has a number of limitations.
Firstly, we have had to assume that all four data sources reflect the same (closed) population. In reality, especially over the long study period, new individuals enter and others leave the population, through initiation of drug use, and death. Secondly, within a given data source, each IDU was assumed to have the same chance of being included (i.e., to have the same 'catchability'). Although we have attempted to address the issue of heterogeneity in being observed within a given data source by conducting stratified analyses, an unknown degree of variability will remain. Subgroups with low catchability might bias estimates of the prevalence of IDU within the HCV-diagnosed population downwards. Finally, violation of the assumed high accuracy of the record-linkage methods could also result in bias. Although the probabilistic methods used by ISD to link HCV Diagnosis with the SMR01/deaths linked dataset have historically low false positive and false negative rates (<5% [9] ), accuracy estimates were not available for the other linkages performed.
In conclusion, the proportion of Scotland's HCV-diagnosed population who were estimated to have acquired their infection through injecting drug use was smaller than if estimated from only the data with non-missing risk information, but once opportunity for capture on the other data sources was increased, the proportion with IDU risk was more similar. Information on the route by which HCV infection is acquired is essential when targeting risk groups with educational and prevention interventions, and is also useful for governmental and public health professionals who develop policy and allocate funding for treatment and care. Our results -indicating a similar high prevalence of IDU among HCV-diagnosed individuals with missing data on risk activities, as among those with risk activity reported -provide evidence that efforts to prevent and treat HCV infection should focus on this risk group. 
